OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS
19 August 2024 - 10:30PM
Business Wire
- Focus of work at JLABS on tunable Antibody Drug Conjugate
linker-based platform
OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the
Company”), an ADC and Immunotherapy research and clinical-stage
biopharmaceutical company, today announced that it has been
accepted into Johnson & Johnson Innovation – JLABS. Through
membership of JLABS, OS Therapies aims to further develop and enter
the clinic with its tunable Antibody Drug Conjugate (ADC)
linker-based platform that relies on pH sensitive linkers &
coating technology to reduce off-target effects to improve safety
and increase the number & diversity of therapeutic payloads
delivered. Through these developments, OS Therapies hopes to offer
improved efficacy versus other ADCs in the market or in
development. Drug candidates developed using OS Therapies’ tunable
ADC platform leverage this unique linker platform to create new
intellectual property for both novel and off-patent targeting
antibodies and drug payloads.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the
identification, development and commercialization of treatments for
Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s
lead asset, is an immunotherapy leveraging the immune-stimulatory
effects of Listeria bacteria to initiate a strong immune response
targeting the HER2 protein. The Company has completed enrollment
for a 41-patient Phase 2b clinical trial of OST-HER2 in resected,
recurrent osteosarcoma, with results expected in the fourth quarter
of 2024. OST-HER2 has completed a Phase 1 clinical study primarily
in breast cancer patients, in addition to showing strong
preclinical efficacy data in various models of breast cancer. In
addition, OS Therapies is advancing its next generation Antibody
Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which
features tunable, tailored antibody-linker-payload candidates. This
platform leverages the Company’s proprietary silicone linker
technology, enabling the delivery of multiple payloads per linker.
For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
forward-looking statements within the meaning of the federal
securities laws. These forward-looking statements and terms such as
“anticipate,” “expect,” “intend,” “may,” “will,” “should” or other
comparable terms involve risks and uncertainties because they
relate to events and depend on circumstances that will occur in the
future. Those statements include statements regarding the offer and
sale of shares, the timing of the listing of OS Therapies’ common
stock on the NYSE American, the timing of the closing of the
offering, the use of the proceeds from the sale of shares of common
stock in the offering, and the intent, belief or current
expectations of OS Therapies and members of its management, as well
as the assumptions on which such statements are based. Prospective
investors are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks and
uncertainties, including those described under the caption “Risk
Factors” and elsewhere in the prospectus filed with the SEC
relating to the offering and that actual results may differ
materially from those indicated by such forward-looking statements.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and, except as required by the
federal securities laws, OS Therapies specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240819756213/en/
Corporate and Media: Jack Doll 410-297-7793
Irpr@ostherapies.com
Investor Relations: Dave Gentry RedChip Companies, Inc.
1-407-644-4256 OSTX@redchip.com
OS Therapies (AMEX:OSTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
OS Therapies (AMEX:OSTX)
Historical Stock Chart
From Sep 2023 to Sep 2024